Japanese growth for Boehringer Ingelheim as Pradaxa filing nears
This article was originally published in Scrip
Boehringer Ingelheim is planning to apply for the Japanese approval of Pradaxa (dabigatran) for stroke prevention in atrial fibrillation patients in the first quarter of next year, only months after the scheduled submissions in other key markets.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.